AR067730A1 - Anticuerpos y fragmentos de anticuerpos anti ephb4 - Google Patents

Anticuerpos y fragmentos de anticuerpos anti ephb4

Info

Publication number
AR067730A1
AR067730A1 ARP080103282A ARP080103282A AR067730A1 AR 067730 A1 AR067730 A1 AR 067730A1 AR P080103282 A ARP080103282 A AR P080103282A AR P080103282 A ARP080103282 A AR P080103282A AR 067730 A1 AR067730 A1 AR 067730A1
Authority
AR
Argentina
Prior art keywords
antibodies
fragments
ephb4
comprise heavy
anti ephb4
Prior art date
Application number
ARP080103282A
Other languages
English (en)
Inventor
Josef Prassler
Andreas Popp
Stefab Steidi
Andreas Menrad
Jorg Willuda
Dieter Zopf
Catrin Pracht
Jens Glienke
Original Assignee
Morphosys Ag
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag, Bayer Schering Pharma Ag filed Critical Morphosys Ag
Publication of AR067730A1 publication Critical patent/AR067730A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se relaciona con anticuerpos y fragmentos de anticuerpos que reconocen específicamente el receptor EphB4, los cuales comprenden cadenas pesadas y cadenas livianas, y comprenden CDR pesadas y livianas, y su uso como medicamento para el tratamiento de la angiogénesis patologica, en particular, en la terapia del cáncer.
ARP080103282A 2007-07-31 2008-07-30 Anticuerpos y fragmentos de anticuerpos anti ephb4 AR067730A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075657A EP2020419A1 (en) 2007-07-31 2007-07-31 Anti ephB4 antibody fragments
US95377107P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
AR067730A1 true AR067730A1 (es) 2009-10-21

Family

ID=38739892

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103282A AR067730A1 (es) 2007-07-31 2008-07-30 Anticuerpos y fragmentos de anticuerpos anti ephb4

Country Status (9)

Country Link
US (1) US20090137002A1 (es)
EP (2) EP2020419A1 (es)
AR (1) AR067730A1 (es)
CL (1) CL2008002233A1 (es)
PA (1) PA8791201A1 (es)
PE (1) PE20090906A1 (es)
TW (1) TW200911836A (es)
UY (1) UY31258A1 (es)
WO (1) WO2009015908A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
WO2011037791A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
EP2494062B1 (en) * 2009-10-28 2016-12-28 Janssen Biotech, Inc. Anti-glp-1r antibodies and their uses
EP2603521A4 (en) * 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
EP3402518A4 (en) 2016-01-14 2019-07-03 Memorial Sloan-Kettering Cancer Center PEPTIDES SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES, DERIVED FROM FOXP3
CN113398267B (zh) * 2020-03-17 2023-05-05 中国医学科学院药物研究所 EphB4作为靶标在筛选增加胰岛素敏感性药物或模型中的应用
WO2023283211A2 (en) * 2021-07-08 2023-01-12 The Children's Medical Center Corporation Cd21 antibodies and uses thereof
CN114409792B (zh) * 2021-12-01 2022-08-12 中山大学附属第五医院 抗EphB4纳米抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
SI1973950T1 (sl) * 2006-01-05 2015-01-30 Genentech, Inc. Anti-EphB4 protitelesa in postopki njihove uporabe

Also Published As

Publication number Publication date
PE20090906A1 (es) 2009-08-08
CL2008002233A1 (es) 2009-10-09
EP2170955A2 (en) 2010-04-07
WO2009015908A2 (en) 2009-02-05
WO2009015908A3 (en) 2009-03-26
TW200911836A (en) 2009-03-16
UY31258A1 (es) 2009-03-02
US20090137002A1 (en) 2009-05-28
EP2020419A1 (en) 2009-02-04
PA8791201A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
AR067730A1 (es) Anticuerpos y fragmentos de anticuerpos anti ephb4
ECSP18073836A (es) Moléculas de unión a bcma y métodos de uso de las mismas
ECSP18038868A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CL2017001916A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso (divisional solicitud 468-2016)
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
CU20150128A7 (es) Conjugados fármaco-anticuerpo
AR096015A1 (es) Conjugados de fármacos con anticuerpos
AR102649A1 (es) Anticuerpos anti-cadherina-p y conjugados anticuerpos-fármacos
CL2008003526A1 (es) Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CR20120522A (es) Pirrolobenzodiacepinas y conjugados de las mismas
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
MX2016013686A (es) Anticuerpos de antigeno anti-tf humanizado.
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
ECSP18010616A (es) Inmunoconjugados de il22
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
PE20142277A1 (es) Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso
AR124605A2 (es) Anticuerpos anti-il-36r
AR119964A2 (es) Anticuerpos anti-cd123 y conjugados y derivados de estos

Legal Events

Date Code Title Description
FB Suspension of granting procedure